Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Avascular Necrosis Market from 2024 to 2025?

Over the past few years, the size of the avascular necrosis market has seen significant expansion. The projections predict that it will rise from $0.81 billion in 2024 to $0.89 billion in 2025, marking a compound annual growth rate (CAGR) of 9.7%. This surge during the earlier period is the result of factors such as the increasing aging population, rising alcohol consumption, advancements in sports medicine, expansion in medical tourism, and the growth of precision medicine.

What Is the Projected Market Size of the Avascular Necrosis Market?

The market size for avascular necrosis is projected to experience significant expansion in the coming years, escalating to $1.27 billion in 2029 with a compound annual growth rate (CAGR) of 9.3%. The anticipated growth in this period is linked to factors such as increasing cases of osteonecrosis related to corticosteroid use, a rise in knee and hip replacement procedures, an uptick in drug approvals, an increase in road accidents, and a surge in bone injury cases. Forecasted trends driving this market include technological innovation, cutting-edge imaging technologies, diagnostic tools based on artificial intelligence, surgically implanted 3D prints, regenerative orthobiologic therapies, and cell therapy.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24476&type=smp

Who are the Major Competitors in the Avascular Necrosis Market Outlook?

Major companies operating in the avascular necrosis market are Stryker Corporation, Massachusetts General Hospital, Zimmer Biomet Holdings Inc., Smith & Nephew plc, Stanford Health Care, Apollo Hospitals Enterprise Limited, Singapore General Hospital Pte Ltd., Fortis Healthcare Limited, Narayana Hrudayalaya Limited, Bumrungrad International Hospital Co. Ltd., Aster DM Healthcare Limited, Mount Elizabeth Hospital Pte Ltd., Gleneagles Hospital Pte Ltd., Shalby Limited, Texas Orthopedic Hospital LLC, Regrow Biosciences Pvt. Ltd., Maxcure Hospitals Limited, Medicover Hospitals Private Limited, Mesoblast Limited, Athersys Inc., Ginger Healthcare Private Limited

What Is Fueling Growth in the Avascular Necrosis Market?

The surging frequency of hip and knee replacement surgeries is projected to drive the growth of the avascular necrosis market in the future. These surgical procedures, which entail the replacement of damaged joints, are employed to alleviate severe pain resulting from avascular necrosis. The escalating rates of such replacements stem from an increased incidence of osteoarthritis, a condition that leads to significant joint pain and mobility problems, often necessitating surgical intervention to mitigate pain and enhance life’s quality. Avascular necrosis, a condition leading to bone tissue death due to inadequate blood supply and eventually joint breakdown, heavily contributes to the rising need for knee and hip replacements. For instance, Curvo Labs, Inc., a U.S. healthcare technology firm, reported in September 2023 that the number of knee replacements in the U.S. rose from 1,235,835 in 2021 to 1,299,084 in 2022. Hence, the rising number of knee and hip replacement surgeries is fueling the avascular necrosis market’s growth. The growth of the avascular necrosis market is also likely to be stimulated by the escalating healthcare expenditure, as it boosts access to improved diagnostic and treatment options. The total outlay on health services, medical products, and treatments across a healthcare system or population constitutes healthcare expenditure. This expenditure is increasing due to the growing presence of chronic diseases that necessitate long-term management, frequent hospital trips, and expensive medications. Such expenditure can enhance avascular necrosis management by ensuring access to prompt diagnosis, advanced therapies, and surgical operations that can better manage the situation and improve patient results. For instance, in April 2025, the American Medical Association pointed out that health spending in the U.S. rose by 7.5% in 2023, reaching $4.9 trillion, or $14,570 per capita, a significant increase from the 4.6% rise in 2022. Consequently, the growing healthcare expenditure is propelling the growth of the avascular necrosis market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24476&type=smp

Which Avascular Necrosis Market Segments Are Growing the Fastest?

The avascular necrosis market covered in this report is segmented –

1) By Type: Trauma Related Avascular Necrosis, Non-Trauma Related Avascular Necrosis

2) By Diagnosis: Imaging, Biopsy, Computed Tomography Scan, Positron Emission Tomography, X-Ray

3) By Treatment Type: Medications, Surgery, Physical Therapy, Lifestyle Changes, Bone Grafting

4) By End-User: Hospitals, Specialty Clinics, Rehabilitation Centers, Ambulatory Surgical Centers, Home Care Settings

Subsegment:

1) By Trauma-Related Avascular Necrosis: Fracture-Induced Avascular Necrosis, Dislocation-Induced Avascular Necrosis, Post-Surgical Avascular Necrosis, Crush Injury-Related Avascular Necrosis, Sports Injury-Associated Avascular Necrosis

2) By Non-Trauma Related Avascular Necrosis: Steroid-Induced Avascular Necrosis, Alcohol-Induced Avascular Necrosis, Sickle Cell Disease-Associated Avascular Necrosis, Lupus-Related Avascular Necrosis, Radiation Therapy-Induced Avascular Necrosis, Idiopathic Avascular Necrosis

Which Industry Trends Are Shaping the Future of the Avascular Necrosis Market?

Leading businesses in the avascular necrosis market are securing regulatory approvals to broaden their offerings, improve therapeutic possibilities, and consolidate their market position. Regulatory approvals define as official consents provided by health regulators permitting a medical product or procedure to be marketed and utilized after achieving safety and efficacy criteria. For example, Regrow Biosciences, a biotech company from India obtained approval from the US Food and Drug Administration in May 2022 to carry out Phase II clinical studies in the US for its drug OSSGROW, used in the treatment of osteonecrosis or avascular necrosis. OSSGROW, an innovative, tailor-made bone cell therapy, was designed by Regrow Biosciences to cure the early to moderate phases (up to stage III) of avascular necrosis also termed as osteonecrosis. The procedure involves extracting mesenchymal stem cells from the patient’s bone marrow and culturing them in a specialized lab to become osteoblasts or bone-forming cells. OSSGROW is seen as a natural, safe, and potentially lasting solution, intending to supersede conventional treatments and joint replacement operations that only alleviate symptoms.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/avascular-necrosis-global-market-report

Which Countries Are Leading the Avascular Necrosis Market?

North America was the largest region in the avascular necrosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the avascular necrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24476

This Report Delivers Insight On:

1. How big is the avascular necrosis market, and how is it changing globally?

2. Who are the major companies in the avascular necrosis market, and how are they performing?

3. What are the key opportunities and risks in the avascular necrosis market right now?

4. Which products or customer segments are growing the most in the avascular necrosis market?

5. What factors are helping or slowing down the growth of the avascular necrosis market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model